Related Experiment Video
Updated: Mar 18, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap
Sanjiv J Shah1, Dalane W Kitzman1, Barry A Borlaug1
1From Division of Cardiology, Department of Medicine, and the Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Sections on Cardiovascular Medicine and Geriatrics, Wake Forest School of Medicine, Winston-Salem, NC (D.W.K.); Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN, (B.A.B.); Department of Physiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands (L.v.H., W.J.P.); Department of Cardiology, Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands (L.v.H.); Department of Medicine, Medical University of South Carolina (MUSC) and the RHJ Department of Veterans Affairs Medical Center, Charleston (M.R.Z.); and Division of Cardiology, Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD (D.A.K.).
Insights
Heart failure with preserved ejection fraction (HFpEF) treatment requires addressing comorbidities and diverse phenotypes. A personalized strategy targets HFpEF-specific signaling pathways for improved outcomes.
Area of Science:
- Cardiology
- Internal Medicine
- Translational Research
Background:
- Heart failure with preserved ejection fraction (HFpEF) is a growing clinical challenge, accounting for 50% of heart failure cases.
- Unlike HF with reduced ejection fraction, HFpEF has shown resistance to traditional neurohumoral inhibition therapies.
- Distinct systemic and myocardial signaling pathways, along with phenotypic diversity, contribute to HFpEF's complexity.
Purpose of the Study:
- To propose a novel treatment strategy for HFpEF that accounts for its specific signaling mechanisms and phenotypic variations.
- To elucidate the role of extracardiac comorbidities in driving cardiac remodeling and dysfunction in HFpEF.
- To identify potential therapeutic targets within the identified signaling cascades.
Main Methods:
- Review of current literature on HFpEF pathophysiology, focusing on systemic inflammation and endothelial dysfunction.
- Analysis of signaling pathways linking comorbidities (metabolic risk, hypertension, renal insufficiency) to cardiac remodeling.
- Exploration of targeted interventions for specific molecular and cellular processes in HFpEF.
Main Results:
- Extracardiac comorbidities drive HFpEF through systemic inflammation and coronary microvascular endothelial dysfunction.
- These mechanisms lead to left ventricular diastolic dysfunction, interstitial fibrosis, and cardiomyocyte stiffening.
- Multiple therapeutic targets identified, including caloric restriction, statins, PDE5 inhibitors, exercise, diuretics, nitrate-nitrite, neprilysin/PDE9 inhibitors, and spironolactone.
Conclusions:
- A personalized therapeutic approach is crucial for managing HFpEF due to its phenotypic diversity.
- Targeting HFpEF-specific signaling cascades offers a promising avenue for treatment development.
- A matrix approach, considering HFpEF presentations and predispositions, can guide personalized therapy selection.
Abstract:
Heart failure (HF) with preserved ejection fraction (EF; HFpEF) accounts for 50% of HF cases, and its prevalence relative to HF with reduced EF continues to rise. In contrast to HF with reduced EF, large trials testing neurohumoral inhibition in HFpEF failed to reach a positive outcome. This failure was recently attributed to distinct systemic and myocardial signaling in HFpEF and to diversity of HFpEF phenotypes. In this review, an HFpEF treatment strategy is proposed that addresses HFpEF-specific signaling and phenotypic diversity. In HFpEF, extracardiac comorbidities such as metabolic risk, arterial hypertension, and renal insufficiency drive left ventricular remodeling and dysfunction through systemic inflammation and coronary microvascular endothelial dysfunction. The latter affects left ventricular diastolic dysfunction through macrophage infiltration, resulting in interstitial fibrosis, and through altered paracrine signaling to cardiomyocytes, which become hypertrophied and stiff because of low nitric oxide and cyclic guanosine monophosphate. Systemic inflammation also affects other organs such as lungs, skeletal muscle, and kidneys, leading, respectively, to pulmonary hypertension, muscle weakness, and sodium retention. Individual steps of these signaling cascades can be targeted by specific interventions: metabolic risk by caloric restriction, systemic inflammation by statins, pulmonary hypertension by phosphodiesterase 5 inhibitors, muscle weakness by exercise training, sodium retention by diuretics and monitoring devices, myocardial nitric oxide bioavailability by inorganic nitrate-nitrite, myocardial cyclic guanosine monophosphate content by neprilysin or phosphodiesterase 9 inhibition, and myocardial fibrosis by spironolactone. Because of phenotypic diversity in HFpEF, personalized therapeutic strategies are proposed, which are configured in a matrix with HFpEF presentations in the abscissa and HFpEF predispositions in the ordinate.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Pathophysiology of Heart Failure
Cardiomyopathy V: Interprofessional Care

